
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Please write to us at: Contact@qvents.in
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on other pharma Quality and Regulatory subjects which you would like Qvents to address. Your feedback helps us making and maintaining the Qvents portal as a useful resource for Pharma professionals
You can also write to us on different Quality events (Deviations, OOS, Complaints, CAPAs and so on), Warning letters, 483s, Recalls, Import Alerts, Audit observations) you would like Qvents to initiate posts and discussions. We will review and get back to you, take up the subjects for discussion in Qvents.
Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
Indian API manufacturer Global Calcium Pvt Ltd was issued a Warning letter by USFDA in January 2025. This was along expected lines, after serious data integrity issues and CGMP violations observed by FDA investigators Justin A. Boyd and Teresa I....
FDA issued Warning letter to two Chinese API manufacturers following for cGMP violations including failing to meet USP specifications, inadequate stability data, deficient cleaning validation and inappropriate controls over incoming material testing. The FDA inspected Wuhu Nuowei Chemistry Co., Ltd...
Health Ministry in India has extended the timeline for implementation of the revised Schedule M by one year for MSMEs. The new timeline for implementation of the revised Schedule M by MSMEs (Micro Small and Medium Enterprises) with a turnover...
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on Pharma Quality and Regulatory topics and subjects you would like Qvents to cover. Your feedback helps us in making and maintaining the Qvents portal as a useful resource for Pharma TechOps professionals. Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
Please feel free to contact us for any enquiries.
Email: contact@qvents.in
Phone: (+91) 9945519525
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on Pharma Quality and Regulatory topics and subjects you would like Qvents to cover. Your feedback helps us in making and maintaining the Qvents portal as a useful resource for Pharma TechOps professionals. Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
Please feel free to contact us for any enquiries.
Email: contact@qvents.in
Phone: (+91) 9945519525
Indian API manufacturer Global Calcium Pvt Ltd was issued a Warning letter by USFDA in January 2025. This was along expected lines, after serious data integrity issues and CGMP violations observed by FDA investigators Justin A. Boyd and Teresa I....
FDA issued Warning letter to two Chinese API manufacturers following for cGMP violations including failing to meet USP specifications, inadequate stability data, deficient cleaning validation and inappropriate controls over incoming material testing. The FDA inspected Wuhu Nuowei Chemistry Co., Ltd...
Health Ministry in India has extended the timeline for implementation of the revised Schedule M by one year for MSMEs. The new timeline for implementation of the revised Schedule M by MSMEs (Micro Small and Medium Enterprises) with a turnover...